Fetal growth and adverse birth outcomes in women receiving prescriptions for acetaminophen during pregnancy

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review


  • The EuroMap Study Group
  • ,
  • Andrew E. Czeizel, Hungary
  • Loljke De Jong
  • ,
  • Lorentz Irgens
  • ,
  • Ulf Bergman
  • ,
  • Charlotte Olesen, Denmark
  • Flemming Hald Steffensen, Denmark
  • Lars Pedersen
  • Rolv Lie
  • ,
  • Corinne de Vries
We studied the association between acetaminophen exposure during pregnancy and the prevalence of congenital abnormalities and fetal growth. Our study included 123 women who had received a prescription of acetaminophen during pregnancy and/or 30 days before conception and 13,329 controls who did not receive any prescription at all. We found more malformations among those who received a prescription with an odds ratio of 2.3 (95% CI 1.0-5.4), but the type of malformations did not indicate a causal link. When restricting the study to first time pregnancies, we identified 58 women who received a prescription of acetaminophen during pregnancy and 30 days before conception and 7472 controls. We found no excess risk of malformation [OR = 0.7 (95% CI 0.1-5.5)], and no evidence that acetaminophen should influence fetal growth.
Original languageEnglish
JournalAmerican Journal of Perinatology
Pages (from-to)321-326
Number of pages6
Publication statusPublished - 1999

    Research areas

  • acetaminophen, pregnancy, congenital malformations, epidemiology

See relations at Aarhus University Citationformats

ID: 248297